Postmenopozal Hormon Replasman Tedavisi
Özet
Dünya Sağlık Örgütü menopozu, over aktivitesinin yitirilmesiyle hormon üretiminin azalması ve menstrüasyonun 12 ay boyunca sonlanması olarak tanımlar. Ortalama 80 yıl olan kadın ömrünün yaklaşık %40'ı postmenopozal dönemde geçmektedir. Bu dönemde sıcak basması, vajinal kuruluk, uykusuzluk gibi semptomlar ile uzun dönemde osteoporoz ve kalp hastalığı riskleri görülebilir. Hormon replasman tedavisi (HRT), hayat kalitesini artıran, vazomotor semptomları azaltan ve osteoporoz riskini düşüren bir yöntemdir. Ancak tedavi, özellikle 10 yıllık kullanımdan sonra endometrium ve meme kanseri riskinde hafif artışa yol açabilir. Uterusu olan kadınlarda endometrium kanseri riskini minimalize etmek için östrojene progesteron eklenmesi gerekirken, histerektomi olmuş kadınlarda progesteron kullanımı gerekmez. HRT; meme kanseri öyküsü, genital kanama, gebelik, aktif karaciğer hastalığı ve tromboemboli varlığında kesinlikle kontrendikedir. Sonuç olarak, HRT kararı bireysel olmalı, hastalar olası risk ve faydalar hakkında detaylıca bilgilendirilerek süreç hekim kılavuzluğunda yönetilmelidir.
The World Health Organization defines menopause as the cessation of cyclic menstruation for 12 months due to the loss of ovarian activity and the subsequent decrease in estrogen and progesterone production. Given that the average female life expectancy is 80 years, approximately 40% of a woman's life is spent in the postmenopausal period. This stage can cause short-term symptoms like hot flashes, vaginal dryness, and insomnia, as well as long-term risks such as osteoporosis and coronary heart disease. Hormone replacement therapy (HRT) aims to eliminate these quality-of-life-disrupting conditions, improve depression, and reduce long-term risks of bone loss and cardiovascular diseases. However, the treatment carries risks, including a slight increase in endometrial and breast cancer rates, particularly after 10 years of use. To minimize endometrial cancer risks in women with an intact uterus, progesterone must be combined with estrogen, whereas it is unnecessary for hysterectomized women. HRT is strictly contraindicated in cases of known or suspected breast cancer, undiagnosed uterine bleeding, pregnancy, active liver disease, and history of thromboembolism. Ultimately, the decision to initiate HRT should be highly individualized and made by the patient under the guidance of a healthcare provider after comprehensive counseling.
Referanslar
Olshansky SJ, Cames BA. Cassel CK. The aging of the human species. Sci Am. 1993;268(4): 46-52.
Palacios S. Current perspectives on the benefits of HRT in menopausal women. Maturitas. 1999;33 Suppl 1: 1-13.
Keating FS, Manassiev N, Stevenson JC. Maximizing the use of HRT: Focus on hysterectomised women. Current Medical Research and Opinion. 1999;15(4): 290-297.
Tang MX, Jacobs D, Stern Y, et al. Effects of estrogens during menopause and age of onset of Alzheimer’s disease. Lancet. 1996;348(9025): 429-432.
Chung THK, Lau TK, Cheung LP, et al. Compliance with hormone replacement therapy in Chinese women in Hong Kong. Maturitas 1998;28(3): 213-219.
Hammond CB. Women’s concerns with hormone replacement therapy – compliance issues. Fertil Steril. 1994;62(6 Suppl 2): 157-60.
Peled Y, Perri T, Pardo Y, et al. Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms; a review. Menopause. 2007;14(3):550-554.
Varma TR. Effect of long-term therapy with estrogen and progesterone on the endometrium of postmenopausal women. Acta Obstet Gynecol Scand 1985;64(1): 41-46.
Paganini Hill T, Ross RK, Hendersen BE. Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study. Br J Cancer. 1989;59(3): 445-447.
Kurman RJ,Kalminski PF, Norris IIJ. The behavior of endometrial hyperplasia: A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985;56(2): 403-412.
Voigt LF, Weiss NS. Chu JR, et al. Progestagen supplementation of exogenous estrogens and risk of endometrial cancer. Lancet. 1991;338(8762): 274-277.
Richeson LS, Wahner MW, Melton LJ, et al. Relative contributions of aging and estrogen deficiency in postmenopausal bone loss. New Engl J Med. 1984;311(20): 1273-1275.
Palacios S. Cancer surveillance during HRT. Int J Fertil 1996;39 Suppl 2: 93-98.
Bergkvist L, Adami HO, Persson O, et al. The risk of breast cancer after estrogen and estrogen-progesterone replacement. New Engl J Med. 1989;321(5): 293-297.
Bergkvist L, Adami HO, Persson O, et al. Prognosîs after breast cancer diagnosed in women exposed to estrogen and estrogen-progesterone replacement therapy. Am J Epidemiol. 1989;130(2): 221-228.
Colditz G A, Stampfer M J, Willet WC, et al. Type of postmenopausal hormone use and risk of breast cancer. 12-year follow-up from the Nurse's Health Study. Cancer Causes Control. 1992;3(5): 433-439.
Dupont WD, Page Di, Rogers 1W, Parl FF. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer. 1989;63(5): 948-957.
